{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:52Z","timestamp":1793647672248,"version":"4.5.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81770646"],"award-info":[{"award-number":["No.81770646"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biliary tract cancers (BTCs) are a series of heterogeneous malignancies that are broadly grouped based on the anatomical site where they arise into subtypes including intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), gallbladder cancer (GBC), and ampulla of Vater cancer (AVC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and Results<\/jats:title>\n                <jats:p>The present study provides an overview of the epidemiology of the various BTCs based on data from the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2018. Distinct differences in both incidence and mortality rates were observed for these BTCs as a function of age, sex, ethnicity, and calendar year. In 2018, BTCs emerged as the fifth most prevalent form of alimentary tract cancer in the USA. While the incidence and mortality of ICC appear to be increasing, the incidence rates of GBC, ECC, and AVC have remained stable, as have the corresponding mortality rates. The most common and deadliest BTCs in 2018 were ICC and GBC among males and females, respectively. The ethnic groups exhibiting the highest incidence rates of these different BTCs were American Indians and Alaska Natives for GBC, and Asian and Pacific Islanders for ICC, ECC, and AVC. The incidence of all of these forms of BTC rose with age. There were some variations in BTCs in terms of staging, locoregional surgical treatments, adjuvant therapies, and prognostic outcomes from 2000 to 2018.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The epidemiological characteristics, staging, locoregional surgical treatments, adjuvant therapies, and prognostic outcomes were distinct for each of these BTCs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02637-8","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T18:02:34Z","timestamp":1672336954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["The epidemiological trends of biliary tract cancers in the United States of America"],"prefix":"10.1186","volume":"22","author":[{"given":"Yong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingda","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"9935","key":"2637_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. The Lancet. 2014;383(9935):2168\u201379.","journal-title":"The Lancet"},{"issue":"3","key":"2637_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jhep.2010.10.010","volume":"54","author":"N Razumilava","year":"2011","unstructured":"Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. J Hepatol. 2011;54(3):577\u20138.","journal-title":"J Hepatol"},{"key":"2637_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2407-2-10","volume":"2","author":"T Patel","year":"2002","unstructured":"Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"2637_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331.","journal-title":"Liver Int"},{"issue":"4","key":"2637_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"C Fitzmaurice","year":"2015","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505\u201327.","journal-title":"JAMA Oncol"},{"issue":"7","key":"2637_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00268-005-7763-7","volume":"29","author":"YY Jan","year":"2005","unstructured":"Jan YY, Yeh CN, Yeh TS, Hwang TL, Chen MF. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg. 2005;29(7):894\u20138.","journal-title":"World J Surg"},{"issue":"7","key":"2637_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1245\/s10434-010-0938-y","volume":"17","author":"SY Cho","year":"2010","unstructured":"Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol. 2010;17(7):1823\u201330.","journal-title":"Ann Surg Oncol"},{"key":"2637_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-34244-3_6","volume":"168","author":"AE Ertel","year":"2016","unstructured":"Ertel AE, Bentrem D, Abbott DE. Gall bladder cancer. Cancer Treat Res. 2016;168:101\u201320.","journal-title":"Cancer Treat Res"},{"issue":"2","key":"2637_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.21873\/invivo.11798","volume":"34","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Frega G, Ricci AD, Palloni A, Abbati F, De Lorenzo S, et al. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis. In Vivo. 2020;34(2):479\u201388.","journal-title":"In Vivo"},{"issue":"12","key":"2637_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1200\/JOP.18.00558","volume":"14","author":"AM Horgan","year":"2018","unstructured":"Horgan AM, Knox JJ. Adjuvant therapy for biliary tract cancers. J Oncol Pract. 2018;14(12):701\u20138.","journal-title":"J Oncol Pract"},{"issue":"7","key":"2637_CR11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ijc.28161","volume":"133","author":"FA Castro","year":"2013","unstructured":"Castro FA, Koshiol J, Hsing AW, Devesa SS. Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. Int J Cancer. 2013;133(7):1664\u201371.","journal-title":"Int J Cancer"},{"issue":"3","key":"2637_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2017.08.017","volume":"16","author":"LA Torre","year":"2018","unstructured":"Torre LA, Siegel RL, Islami F, Bray F, Jemal A. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol. 2018;16(3):427\u201337.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10272","key":"2637_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. The Lancet. 2021;397(10272):428\u201344.","journal-title":"The Lancet"},{"issue":"5","key":"2637_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594\u20139.","journal-title":"Oncologist"},{"issue":"16","key":"2637_CR15","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2637_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2637_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.hpb.2017.05.010","volume":"19","author":"M Ghidini","year":"2017","unstructured":"Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB (Oxford). 2017;19(9):741\u20138.","journal-title":"HPB (Oxford)"},{"key":"2637_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100335","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: \u201cAnd Yet It Moves!\u201d Cancer Treat Res Commun. 2021;27: 100335.","journal-title":"Cancer Treat Res Commun"},{"issue":"12","key":"2637_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/jnci\/djj234","volume":"98","author":"TM Welzel","year":"2006","unstructured":"Welzel TM, McGlynn KA, Hsing AW, O\u2019Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98(12):873\u20135.","journal-title":"J Natl Cancer Inst"},{"issue":"29","key":"2637_CR20","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/sim.3733","volume":"28","author":"LX Clegg","year":"2009","unstructured":"Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28(29):3670\u201382.","journal-title":"Stat Med"},{"issue":"1","key":"2637_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"GL Tyson","year":"2011","unstructured":"Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173\u201384.","journal-title":"Hepatology"},{"issue":"3","key":"2637_CR22","doi-asserted-by":"publisher","first-page":"107327481772924","DOI":"10.1177\/1073274817729245","volume":"24","author":"NN Massarweh","year":"2017","unstructured":"Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245.","journal-title":"Cancer Control"},{"issue":"3","key":"2637_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2188\/jea.JE20130122","volume":"24","author":"M Utada","year":"2014","unstructured":"Utada M, Ohno Y, Tamaki T, Sobue T, Endo G. Long-term trends in incidence and mortality of intrahepatic and extrahepatic bile duct cancer in Japan. J Epidemiol. 2014;24(3):193\u20139.","journal-title":"J Epidemiol"},{"issue":"2","key":"2637_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bpg.2015.02.003","volume":"29","author":"A Bergquist","year":"2015","unstructured":"Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221\u201332.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"2637_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72(1):95\u2013103.","journal-title":"J Hepatol"},{"issue":"6","key":"2637_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/aje\/kwt322","volume":"179","author":"L Nogueira","year":"2014","unstructured":"Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F, Koshiol J. Gallstones, cholecystectomy, and risk of digestive system cancers. Am J Epidemiol. 2014;179(6):731\u20139.","journal-title":"Am J Epidemiol"},{"issue":"8239","key":"2637_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(81)90366-4","volume":"2","author":"AK Diehl","year":"1981","unstructured":"Diehl AK, Beral V. Cholecystectomy and changing mortality from gallbladder cancer. Lancet. 1981;2(8239):187\u20139.","journal-title":"Lancet"},{"issue":"2","key":"2637_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.gene.2013.08.058","volume":"530","author":"R Rai","year":"2013","unstructured":"Rai R, Sharma KL, Misra S, Kumar A, Mittal B. PSCA gene variants (rs2294008 and rs2978974) confer increased susceptibility of gallbladder carcinoma in females. Gene. 2013;530(2):172\u20137.","journal-title":"Gene"},{"issue":"12","key":"2637_CR29","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/jnci\/djz103","volume":"111","author":"EE McGee","year":"2019","unstructured":"McGee EE, Jackson SS, Petrick JL, Van Dyke AL, Adami HO, Albanes D, et al. Smoking, alcohol, and biliary tract cancer risk: a pooling project of 26 prospective studies. J Natl Cancer Inst. 2019;111(12):1263\u201378.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 7","key":"2637_CR30","doi-asserted-by":"publisher","first-page":"vii345","DOI":"10.1093\/annonc\/mdq420","volume":"21","author":"JW Valle","year":"2010","unstructured":"Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"2637_CR31","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.3747\/co.27.5465","volume":"27","author":"M Kish","year":"2020","unstructured":"Kish M, Chan K, Perry K, Ko YJ. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers. Curr Oncol. 2020;27(1):e20\u20136.","journal-title":"Curr Oncol"},{"issue":"5","key":"2637_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17474124.2021.1853527","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15(5):527\u201336.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"2637_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13543784.2021.1837774","volume":"30","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2021;30(4):317\u201324.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"2637_CR34","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640\u20139.","journal-title":"N Engl J Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02637-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T18:02:59Z","timestamp":1672336979000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02637-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2637"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02637-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"546"}}